| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.09. | Avalon GloboCare Corp. - 8-K, Current Report | 3 | SEC Filings | ||
| 28.08. | Avalon GloboCare Corp. - 8-K, Current Report | 3 | SEC Filings | ||
| 28.08. | Avalon GloboCare Corp.: Avalon GloboCare to Launch Online Sales of KetoAir Breathalyzer in the United Kingdom | 1 | GlobeNewswire (USA) | ||
| 14.08. | Avalon GloboCare Corp. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | Avalon GloboCare Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.07. | Avalon GloboCare verlängert Fälligkeit von vorrangig besicherter Schuldverschreibung | 1 | Investing.com Deutsch | ||
| AVALON GLOBOCARE Aktie jetzt für 0€ handeln | |||||
| 28.07. | Avalon GloboCare Corp.: Avalon GloboCare Enters into Distribution Agreement with Saga Health for KetoAir Targeting First Responders | 2 | GlobeNewswire (USA) | ||
| 28.07. | Avalon GloboCare Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.07. | Avalon GloboCare sichert sich 300.000 US-Dollar durch Verkauf von Vorzugsaktien | 1 | Investing.com Deutsch | ||
| 18.07. | Avalon GloboCare Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.07. | Neues Patent für Zelltherapie treibt Aktie von Avalon GloboCare an | 1 | Investing.com Deutsch | ||
| 14.07. | Avalon GloboCare stock soars after securing new CAR-T cell patent | 1 | Investing.com | ||
| 14.07. | Avalon GloboCare secures Hong Kong patent for CAR-T cell technology | 2 | Investing.com | ||
| 14.07. | Avalon GloboCare Corp.: Avalon GloboCare Announces Patent Issuance for Novel CAR-T and CAR-NK Cell Technology in Hong Kong | 160 | GlobeNewswire (Europe) | FREEHOLD, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced the issuance... ► Artikel lesen | |
| 09.07. | Avalon GloboCare gibt Wandelschuldverschreibungen im Wert von 200.000 $ aus | 2 | Investing.com Deutsch | ||
| 09.07. | Avalon GloboCare Corp. - 8-K, Current Report | 4 | SEC Filings | ||
| 26.06. | Avalon GloboCare, Qi To Co-develop VOC Nanosensor-based Cannabis Breathalyzer | 1 | RTTNews | ||
| 26.06. | Avalon GloboCare Corp.: Avalon GloboCare and Qi Diagnostics Enter into Definitive Agreement to Co-Develop Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving | 2 | GlobeNewswire (USA) | ||
| 26.06. | Avalon GloboCare Corp. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.06. | Avalon GloboCare Corp. - S-4/A, Registration of securities, business combinations | - | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 89,45 | +1,82 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
| EVOTEC | 6,704 | +0,09 % | Evotec Aktie: Strohfeuer oder klappt es diesmal? | Die Evotec Aktie zeigt Stärke - aber diesmal auch für eine längere Zeit? Seit dem 26. September hat sich die TecDAX-notierte Biotech-Aktie von 5,882 Euro um mehr als einen Euro verteuert. Am gestrigen... ► Artikel lesen | |
| CUREVAC | 4,650 | +0,43 % | CureVac-Aktie am Scheideweg: Explodiert der Kurs jetzt - oder droht der völlige Absturz?! Anleger in Alarmbereitschaft!!! | ||
| AMGEN | 251,10 | +0,46 % | Amgen Launches AmgenNow, Direct-to-patient Program; Available To Repatha Patients | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha or evolucumab. Repatha will be available through AmgenNow at a... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,420 | +1,85 % | Why Shares in Viking Therapeutics Surged This Week | ||
| DEFENCE THERAPEUTICS | 0,540 | 0,00 % | Defence Therapeutics Inc.: Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025 | Montreal, Quebec--(Newsfile Corp. - October 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug... ► Artikel lesen | |
| IDEXX LABORATORIES | 532,80 | 0,00 % | IDEXX beruft Tech-Expertin Karen Peacock in den Verwaltungsrat | ||
| NUREXONE BIOLOGIC | 0,614 | +2,68 % | Breaking News: Erblindete Augen erholen sich zu 100%! | ||
| ABIVAX | 85,00 | +6,25 % | EQS-News: ABIVAX: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies | EQS-News: ABIVAX
/ Key word(s): Conference/Study results
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without... ► Artikel lesen | |
| IBIO | 0,690 | +1,47 % | iBio, Inc.: iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update | SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 30,460 | -0,13 % | ARROWHEAD PHARMACEUTICALS, INC. - 10-K/A, Annual Report | ||
| ADAPTIMMUNE THERAPEUTICS | 0,151 | -7,36 % | Adaptimmune Therapeutics PLC: Adaptimmune Reports Q2 Financial Results and Provides Business Update | Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 2,345 | +7,82 % | BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements | NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 4,470 | +3,71 % | Voyager Therapeutics, Inc.: Voyager Reports Second Quarter 2025 Financial and Operating Results | - Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer's disease franchise... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 8,050 | +0,88 % | Anavex presents oral blarcamesine data at Alzheimer Europe Conference |